For the first time, a study has been published in which Canadian researchers have stated "successful validation and clinical application" of a point-of-care genetic test in medicine. This test is a quick and bedside test which, before enduring PCI , helps in identifying carriers of the CYP2C19*2 allele.
For conducting this RAPID GENE study, patients were randomly chosen to undertake this bedside testing. Then, all those who were discovered carrying allele, instead of giving clopidogrel post-PCI treatment, were treated with prasugrel (Effient, Lilly/Daiichi).
After seven days of the procedure, these patients were again reviewed and it was revealed that they are less likely to pose high on-treatment platelet reactivity in comparison to those patients who did not undergo point-of-care testing but were differentiated as the carriers of the CYP2C19*2 allele.
According to senior author Dr. Derek So, of the University of Ottawa Heart Institute, rapid gene study is the first one to commence and authenticate this first point-of-care genetic testing device in the history of clinical medicine. It was considered as a quite arduous and lengthy procedure looking out for highly skilled personnel and expensive tools and equipments. Due to these reasons, it was earlier never used in clinical practices and researches.
He said: “The development of a simple bedside genetic test that can be performed by nurses with no prior training in genetics promises to overcome many of these previous obstacles”.
- Finally a $7 Billion Settlement for Citigroup
- Discussions In Progress for Merger of Tobacco Businesses: Reynolds to Acquire Lorillard
- Amazon Seeks Permission to Fly Drones for Delivery of Packages from FAA
- Wells Fargo Reports a Profit
- Abbott hits JV deal with Fonterra to operate diary farms in China